Literature DB >> 2688823

Myogenic regulation of dystrophin gene expression.

H J Klamut, E E Zubrzycka-Gaarn, D E Bulman, S B Malhotra, S E Bodrug, R G Worton, P N Ray.   

Abstract

Muscle-specific transcriptional regulation of DMD gene expression has been inferred from both the histopathology of the disease and, more recently, from the use of cDNA sequences to detect DMD gene transcripts by Northern blot, RNase protection, in situ hybridization, and polymerase chain reaction (PCR) analyses. Several muscle-specific genes have been shown to be transcriptionally activated early in myogenesis and a number of cis-acting promoter elements required for muscle-specific transcriptional induction have been described. In this report we review our recent progress on studies of the mechanisms underlying myogenic regulation of dystrophin gene expression. Indirect immunofluorescence has been used to demonstrate that dystrophin is present at the muscle cell surface very early in the myogenic program. The cloning and sequencing of the dystrophin gene promoter reveals the presence of pre-defined muscle-specific cis-acting promoter elements. Functional assays provide evidence that these upstream sequences are capable of regulating DMD gene expression in a cell-and developmental stage-specific manner.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688823     DOI: 10.1093/oxfordjournals.bmb.a072352

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  7 in total

1.  Stability of the human dystrophin transcript in muscle.

Authors:  C N Tennyson; Q Shi; R G Worton
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

2.  A muscle-specific enhancer within intron 1 of the human dystrophin gene is functionally dependent on single MEF-1/E box and MEF-2/AT-rich sequence motifs.

Authors:  H J Klamut; L O Bosnoyan-Collins; R G Worton; P N Ray
Journal:  Nucleic Acids Res       Date:  1997-04-15       Impact factor: 16.971

3.  Identification of a mutation in the promoter region of the dystrophin gene in a patient with atypical Becker muscular dystrophy.

Authors:  K M Bushby; N J Cleghorn; A Curtis; I D Haggerty; L V Nicholson; M A Johnson; J B Harris; S S Bhattacharya
Journal:  Hum Genet       Date:  1991-12       Impact factor: 4.132

4.  Heterokaryon myotubes with normal mouse and Duchenne nuclei exhibit sarcolemmal dystrophin staining and efficient intracellular free calcium control.

Authors:  W F Denetclaw; G Bi; D V Pham; R A Steinhardt
Journal:  Mol Biol Cell       Date:  1993-09       Impact factor: 4.138

5.  Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin.

Authors:  D E Bulman; E G Murphy; E E Zubrzycka-Gaarn; R G Worton; P N Ray
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

6.  Screening for mutations in the muscle promoter region and for exonic deletions in a series of 115 DMD and BMD patients.

Authors:  L Vitiello; M L Mostacciuolo; S Oliviero; F Schiavon; L Nicoletti; C Angelini; G A Danieli
Journal:  J Med Genet       Date:  1992-02       Impact factor: 6.318

7.  Integration of expressed sequence tag data flanking predicted RNA secondary structures facilitates novel non-coding RNA discovery.

Authors:  Paul M Krzyzanowski; Feodor D Price; Enrique M Muro; Michael A Rudnicki; Miguel A Andrade-Navarro
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.